<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511667</url>
  </required_header>
  <id_info>
    <org_study_id>0941-005</org_study_id>
    <secondary_id>2007_595</secondary_id>
    <nct_id>NCT00511667</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in
      patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily
      MK-0941 in subjects with T2DM with or without adequate control on metformin will be
      sufficiently safe and well tolerated to permit continued clinical investigation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Any Clinical Adverse Experience</measure>
    <time_frame>Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants Discontinued Because of Any Clinical Adverse Experience</measure>
    <time_frame>Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC0-24) of MK-0941 After Multiple Doses of MK0941</measure>
    <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of MK-0941 After Multiple Doses of MK-0941</measure>
    <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of MK-0941 After Multiple Doses of MK-0941</measure>
    <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (T1/2) of MK-0941 After Multiple Doses of MK0941</measure>
    <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941</measure>
    <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK0941</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0941</intervention_name>
    <description>MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day</description>
    <arm_group_label>MK0941</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonsmoking Male or Female (of non-child bearing potential)

          -  Diagnosis of Type 2 Diabetes and is being treated with diet and exercise alone or with
             less than 3 oral anti-hyperglycemic agents

          -  Panel E only (MK0941 60 mg before 2 meals each day): diagnosis of Type 2 Diabetes and
             is on a dose of metformin of greater than or equal to 1500 mg for 8 weeks or more

        Exclusion Criteria:

          -  Subject is on insulin or a peroxisome proliferator-activated receptor (PPAR) agonist

          -  Subject is on 3 or more oral anti-diabetes medications

          -  Subject has a history of type 1 diabetes

          -  Subject has a diagnosis of glaucoma or is blind

          -  Subject has had trauma to one or both eyes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>April 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2012</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-0941</title>
          <description>All participants receiving any dose of MK-0941</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>All participants receiving any dose of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0941</title>
          <description>All participants receiving any dose of MK-0941</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>All participants receiving any dose of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>29 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Any Clinical Adverse Experience</title>
        <time_frame>Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MK-0941</title>
            <description>All participants receiving any dose of MK-0941</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants receiving any dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Any Clinical Adverse Experience</title>
          <units>percentage of of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC0-24) of MK-0941 After Multiple Doses of MK0941</title>
        <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panel A: MK-0941 10 mg</title>
            <description>MK-0941 10 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: MK-0941 20 mg</title>
            <description>MK-0941 20 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: MK-0941 40 mg Day 7</title>
            <description>MK-0941 40 mg before each meal for 7 days. Sampling began after dosing on Day 7. These participants are different from those in Panel D.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: MK-0941 40 mg Day 13</title>
            <description>MK-0941 40 mg before each meal for 13 days. Sampling began after dosing on Day 13. These participants are different from those in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: MK-0941 60 mg</title>
            <description>MK-0941 60 mg before 2 meals each day for 14 days. Sampling began after dosing on Day 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC0-24) of MK-0941 After Multiple Doses of MK0941</title>
          <units>nM-hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2343.29" spread="253.73"/>
                    <measurement group_id="O2" value="3789.25" spread="1002.05"/>
                    <measurement group_id="O3" value="8387.74" spread="2102.17"/>
                    <measurement group_id="O4" value="7673.77" spread="3616.45"/>
                    <measurement group_id="O5" value="8692.07" spread="2681.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of MK-0941 After Multiple Doses of MK-0941</title>
        <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panel A: MK-0941 10 mg</title>
            <description>MK-0941 10 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: MK-0941 20 mg</title>
            <description>MK-0941 20 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: MK-0941 40 mg Day 7</title>
            <description>MK-0941 40 mg before each meal for 7 days. Sampling began after dosing on Day 7. These participants are different from those in Panel D.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: MK-0941 40 mg Day 13</title>
            <description>MK-0941 40 mg before each meal for 13 days. Sampling began after dosing on Day 13. These participants are different from those in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: MK-0941 60 mg</title>
            <description>MK-0941 60 mg before 2 meals each day for 14 days. Sampling began after dosing on Day 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of MK-0941 After Multiple Doses of MK-0941</title>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.35" spread="88.54"/>
                    <measurement group_id="O2" value="364.96" spread="151.25"/>
                    <measurement group_id="O3" value="841.57" spread="348.34"/>
                    <measurement group_id="O4" value="648.49" spread="159.73"/>
                    <measurement group_id="O5" value="1145.81" spread="330.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of MK-0941 After Multiple Doses of MK-0941</title>
        <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panel A: MK-0941 10 mg</title>
            <description>MK-0941 10 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: MK-0941 20 mg</title>
            <description>MK-0941 20 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: MK-0941 40 mg Day 7</title>
            <description>MK-0941 40 mg before each meal for 7 days. Sampling began after dosing on Day 7. These participants are different from those in Panel D.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: MK-0941 40 mg Day 13</title>
            <description>MK-0941 40 mg before each meal for 13 days. Sampling began after dosing on Day 13. These participants are different from those in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: MK-0941 60 mg</title>
            <description>MK-0941 60 mg before 2 meals each day for 14 days. Sampling began after dosing on Day 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of MK-0941 After Multiple Doses of MK-0941</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="6.43" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.0" spread="9.35" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O3" value="1.0" spread="34.95" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="1.0" spread="24.27" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O5" value="2.0" spread="82.68" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (T1/2) of MK-0941 After Multiple Doses of MK0941</title>
        <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panel A: MK-0941 10 mg Before Each Meal</title>
            <description>MK-0941 10 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: MK-0941 20 mg</title>
            <description>MK-0941 20 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: MK-0941 40 mg Day 7</title>
            <description>MK-0941 40 mg before each meal for 7 days. Sampling began after dosing on Day 7. These participants are different from those in Panel D.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: MK-0941 40 mg Day 13</title>
            <description>MK-0941 40 mg before each meal for 13 days. Sampling began after dosing on Day 13. These participants are different from those in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: MK-0941 60 mg</title>
            <description>MK-0941 60 mg before 2 meals each day for 14 days. Sampling began after dosing on Day 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (T1/2) of MK-0941 After Multiple Doses of MK0941</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="5.2"/>
                    <measurement group_id="O2" value="11.4" spread="2.2"/>
                    <measurement group_id="O3" value="8.4" spread="6.3"/>
                    <measurement group_id="O4" value="10.1" spread="3.5"/>
                    <measurement group_id="O5" value="11.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941</title>
        <time_frame>Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panel A: MK-0941 10 mg</title>
            <description>MK-0941 10 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: MK-0941 20 mg</title>
            <description>MK-0941 20 mg before each meal for 5 days. Sampling began after dosing on Day 5.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: MK-0941 40 mg Day 7</title>
            <description>MK-0941 40 mg before each meal for 7 days. Sampling began after dosing on Day 7. These participants are different from those in Panel D.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: MK-0941 40 mg Day 13</title>
            <description>MK-0941 40 mg before each meal for 13 days. Sampling began after dosing on Day 13. These participants are different from those in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: MK-0941 60 mg</title>
            <description>MK-0941 60 mg before 2 meals each day for 14 days. Sampling began after dosing on Day 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941</title>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.75" spread="6.43"/>
                    <measurement group_id="O2" value="42.99" spread="9.35"/>
                    <measurement group_id="O3" value="95.07" spread="34.95"/>
                    <measurement group_id="O4" value="76.89" spread="24.27"/>
                    <measurement group_id="O5" value="149.30" spread="82.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Discontinued Because of Any Clinical Adverse Experience</title>
        <time_frame>Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MK-0941</title>
            <description>All participants receiving any dose of MK-0941</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants receiving any dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Discontinued Because of Any Clinical Adverse Experience</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All other adverse experiences</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 30 days after last dose of study drug (14 days for participants receiving MK-0941 40 mg before each meal)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MK-0941</title>
          <description>All participants receiving any dose of MK-0941</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>All participants receiving any dose of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

